Omachi, Takemasa
Ohara, Makoto http://orcid.org/0000-0002-6137-5493
Fujikawa, Tomoki
Kohata, Yo
Sugita, Hiroe
Irie, Shunichiro
Terasaki, Michishige
Mori, Yusaku
Fukui, Tomoyasu
Yamagishi, Sho-ichi
Clinical trials referenced in this document:
Documents that mention this clinical trial
Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study
https://doi.org/10.1007/s13300-023-01493-3
Article History
Received: 11 September 2023
Accepted: 10 October 2023
First Online: 25 October 2023
Declarations
:
: Makoto Ohara has received lecture fees from Eli Lilly Japan K.K. Yusaku Mori holds an endowed chair funded by Ono Pharmaceutical Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd. Sho-Ichi Yamagishi has received lecture fees from Eli Lilly Japan K.K, Bayer Yakuhin, Ltd., Sanofi K.K., and Novo Nordisk Pharma, Japan. Sho-Ichi Yamagishi, Tomoyasu Fukui, Yo Kohata, Hiroe Sugita, Takemasa Omachi, Shunichiro Irie, Michishige Terasaki and Tomoki Fujikawa declare that they have no conflicts of interest.
: All procedures were followed according to the ethical standards of the responsible committee on human experimentation (institutional and national) and/or the Helsinki Declaration of 1964 and later versions. Informed consent or an acceptable alternative was obtained from all patients included in the study. The study was approved by the Ethics Committee of Showa University (approval number 3292; date of approval, 19 November 2020), and was registered with the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN000042670). The treatment costs were covered by insurance.